No Difference Found in Continuous vs Intermittent Meropenem Administration

The Mercy Trial compared continuous infusion versus intermittent administration of Meropenem in critically ill patients with sepsis and septic shock. However, the trial did not find any significant difference between the two strategies in terms of reducing mortality or emergence of drug-resistant bacteria. The study enrolled 607 patients and the primary outcome was a composite of 28-day mortality and emergence of extensive or pan-drug-resistant bacteria. The results showed no statistical significance between the continuous and intermittent administration groups. Subgroup analyses were also conducted, but no significant differences were found. The study highlighted the challenge of dealing with multidrug resistance and the need for alternative interventions to reduce mortality and drug resistance.